Safety, Effectiveness and Immunogenicity of heterologous mRNA-1273 Boost

South Africa

Reference ID

SafetyEffectivenessandImmunogenicityofheterologousmRNA-1273Boost

Producer(s)

Nigel Garrett, Tarylee Reddy, Nonhlanhla Yende-Zuma, Azwidhwi Takalani, Kubashni Woeber, Annie Bodenstein, Phumeza Jonas, Imke Engelbrecht, Waasila Jassat, Harry Moultrie, Debbie Bradshaw, Ishen Seocharan, Jackline Odhiambo, Kentse Khuto, Simone I. Richardson, Millicent A. Omondi, Rofhiwa Nesamari,

Metadata

Documentation in PDF DDI/XML JSON

Created on

Apr 29, 2024

Last modified

Apr 29, 2024

Page views

25329

Downloads

addtional_comments (addtional_comments)

Data file: SHERPA_Safetydata

Overview

Valid: 5

Type: Discrete

Width: 255

Range: -

Format: character

Questions and instructions

Categories

Value	Cases
Only site redness observed in the injection site.	1	20%
Participant contacted telephonically and confirmed all local reactions resolved by 23/07/2022	1	20%
Participant reported of feeling dizziness. Post vaccination. No medication taken and clinically stable	1	20%
Ppt given analgesia: Panado 500mg TDS PO (5/7)	1	20%
none	1	20%

Warning: these figures indicate the number of cases found in the data file. They cannot be interpreted as summary statistics of the population of interest.

Back to Catalog